Results 11 to 20 of about 117,096 (113)

Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age. [PDF]

, 2015
BACKGROUND:Hizentra® (IGSC 20%) is a 20% liquid IgG product approved for subcutaneous administration in adults and children 2 years of age and older who have primary immunodeficiency disease (PIDD). There is limited information about the use of IGSC 20 %
Atkinson, Thomas Prescott, Bonilla, Francisco A, Dorsey, Morna, Gallagher, Joel L, Haddad, Elie, Heimall, Jennifer, Kobrynski, Lisa, Morris, David, Ochs, Hans D, Patel, Niraj C, Wahlstrom, Justin   +10 more
core   +2 more sources

Primary Immunodeficiency Diseases in the Newborn

Northern Clinics of Istanbul, 2020
The normal neonate's immune system is anatomically completed but antigenically inexperienced and shows somewhat decreased role of a number of immunological pathways. Aside from anatomic characteristics (e.g., thin skin and mucosal barriers) of newborn, weakened pro-inflammatory and T-helper cell type 1 cytokine release and lessened cell-mediated ...
openaire   +3 more sources

Punica granatum (Pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide [PDF]

, 2004
BACKGROUND: For ≈ 24 years the AIDS pandemic has claimed ≈ 30 million lives, causing ≈ 14,000 new HIV-1 infections daily worldwide in 2003. About 80% of infections occur by heterosexual transmission.
A Robert Neurath, A Stone, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, Asim K Debnath, B Conde-Petit, C Berset, C Ma, CD Pilcher, CD Rizzuto, CW Davis, DH Schwartz, DJ Bacon, E Poyrazoglu, EA Merritt, EG Cormier, G Zhang, H Blaak, H Brown, J Moore, JM Johnson, JP Moore, L Hammar, L Wu, M Hsu, M Seguchi, MA Skinner, N DeTommasi, N Mahmood, N Mahmood, Nathan Strick, P Langley, P Suphaphiphat, P Tomasik, P Westervelt, P Westervelt, PD Kwong, PJ Kraulis, Q Hu, Q Zhao, R Pantophlet, R Shattock, R Stute, R Weiss, RJ Shattock, RJ Shattock, RN Fichorova, RN Fichorova, RS Veazey, S Garg, S Gartner, S Laal, S Liu, S-T Hsu, SH Xiang, TC Pierson, UNAIDS, VJ Tomazic-Jezic, WC Greene, WR Yao, Y Van Herrewege, Yun-Yao Li   +66 more
core   +3 more sources

Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120 [PDF]

, 2001
BACKGROUND: Cellulose acetate phthalate (CAP), a pharmaceutical excipient used for enteric film coating of capsules and tablets, was shown to inhibit infection by the human immunodeficiency virus type 1 (HIV-1) and several herpesviruses. CAP formulations
A Boyum, A Robert Neurath, A Trkola, A Trkola, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, Asim K Debnath, CD Rizzuto, CK Lapham, CM Javan, DR Burton, DR Littman, EA Berger, F Cocchi, G Alkhatib, H Choe, H Deng, J Bilello, JA Este, JC Lee, K Javaherian, KH Manson, L Wu, L Xiao, M Baba, M Baba, M Moulard, M Thali, MA Skinner, MC Peitsch, Nathan Strick, P Greenhead, PD Kwong, RA Anderson, RA Maguire, RF Speck, RJ Shattock, S Harada, S Laal, S Matsushita, S Rusconi, S Shaunak, T Dragic, T Gyotoku, T Kawamura, T Muster, TN Hart, WR Melander, Y Feng, YI Rumyantseva, Yun-Yao Li   +55 more
core   +3 more sources

Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children [PDF]

, 2017
AW and JK are supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of AberdeenPeer reviewedPublisher ...
King, Jill, Lehrnbecher, Thomas, Pana, Zoi-Dorothea, Steinbach, William J., Warris, Adilia   +4 more
core   +1 more source

Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study [PDF]

, 2019
We assessed the health-related quality of life (HRQoL) in CVID adults receiving different schedules of immunoglobulin replacement therapy (IgRT) by intravenous (IVIG), subcutaneous (SCIG), and facilitated (fSCIG) preparations.
Agostini, Carlo, Bonanni, Livia, Carrabba, Maria, Cinetto, Francesco, Crescenzi, Ludovica, Fabio, Giovanna, Farrugia, Albert, Milito, Cinzia, Neri, Raffaella, Pecoraro, Antonio, Pulvirenti, Federica, Quinti, Isabella, Spadaro, Giuseppe, Tabolli, Stefano   +13 more
core   +2 more sources

A case of acanthosis nigricans in a HIV-infected patient [PDF]

, 2020
Background: To date, very little information is available concerning the relationship between acanthosis nigricans (AN) and infection with human immunodeficiency virus type 1 (HIV-1).
De Vincentiis, Ludovica, Di Paolo, Marcello, Iacovelli, Alessandra, Mezzaroma, Ivano, Palange, Paolo, Soda, Giuseppe   +5 more
core   +1 more source

Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. [PDF]

, 2020
Since 2013, the International Union of Immunological Societies (IUIS) expert committee (EC) on Inborn Errors of Immunity (IEI) has published an updated phenotypic classification of IEI, which accompanies and complements their genotypic classification ...
Ailal, Fatima, Al-Herz, Waleed, Bousfiha, Aziz, Casanova, Jean-Laurent, Chatila, Talal, Cunningham-Rundles, Charlotte, Etzioni, Amos, Franco, Jose Luis, Holland, Steven M, Jeddane, Leila, Klein, Christoph, Morio, Tomohiro, Ochs, Hans D, Oksenhendler, Eric, Picard, Capucine, Puck, Jennifer, Sullivan, Kathleen E, Tangye, Stuart G, Torgerson, Troy R   +18 more
core  

Anti-HIV-1 activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles [PDF]

, 2002
BACKGROUND: Cellulose acetate phthalate (CAP), a promising candidate microbicide for prevention of sexual transmission of the human immunodeficiency virus type 1 (HIV-1) and other sexually transmitted disease (STD) pathogens, was shown to inactivate HIV ...
A Nicholls, A Robert Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AS Dimitrov, Asim K Debnath, CE Parker, CH Chen, CM Carr, CM Carr, DC Chan, DC Chan, DL LeDuc, DR Littman, E de Rosny, EG Cormier, EG Cormier, GB Melikyan, H Deng, I Munoz-Barroso, J Bentz, J Chen, JA McKeating, JJ Skehel, K Tan, KH Manson, M Farzan, M Lu, M Thali, MK Gorny, Nathan Strick, P Lusso, PD Kwong, PL Jones, QJ Sattentau, QJ Sattentau, QJ Sattentau, R Wyatt, R Wyatt, RA Furuta, RL Willey, RW Doms, S Gartner, S Jiang, S Jiang, SA Gallo, Shibo Jiang, SL Orloff, SP Layne, T Gyotoku, T Kawamura, T Korte, T Weber, T-C Chou, TN Hart, U Moebius, VA Johnson, W Weissenhorn, W Weissenhorn, X-Z Pan, Y Kliger, Yun-Yao Li   +67 more
core   +3 more sources

Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement [PDF]

, 2014
Secondary antibody deficiency can occur as a result of haematological malignancies or certain medications, but not much is known about the clinical and immunological features of this group of patients as a whole. Here we describe a cohort of 167 patients
AA Bousfiha, B Gathmann, B Gathmann, B Piqueras, B Seymour, C Casulo, C Wehr, DF Florescu, E Becerra, E Castigli, ES Resnick, FA Bonilla, G Gunther, H Chapel, H Chapel, H Griffiths, Hilary J. Longhurst, HM Chapel, I De La Torre, I Quinti, J Blore, J Shortt, JA Freeman, JD Edgar, John Dempster, JS Orange, JS Orange, K Warnatz, K Warnatz, L Mouthon, Lorena Lorenzo, M Lucas, M Makatsori, M Yomota, Matthaios Speletas, Matthew Buckland, ME Conley, ME Rose, MJ Boumans, N Ozaras, N Venhoff, NH Yip, P Bright, P McLaughlin, P Wood, R Herriot, S Baris, S Bernatsky, S Molica, Sai S. Duraisingham, Sofia Grigoriadou, SS Duraisingham, T Kawano, U Salzer, W Al-Herz, W Strober   +55 more
core   +7 more sources